<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Aztreonam (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Aztreonam (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Aztreonam (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="104068" href="/d/html/104068.html" rel="external">see "Aztreonam (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="104069" href="/d/html/104069.html" rel="external">see "Aztreonam (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F29768890"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Azactam</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F29837372"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Miscellaneous</span></li></ul></div>
<div class="block don drugH1Div" id="F53462695"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Gestational age-directed dosing</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2021'])">Ref</a></span>): IV, IM:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Higher doses may be required for treatment of meningitis.</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">Gestational Age</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Postnatal Age</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">&lt;34 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤7 days</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">&gt;7 days</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 mg/kg/dose every 8 hours</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">≥34 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤7 days</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 mg/kg/dose every 8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">&gt;7 days</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 mg/kg/dose every 6 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-3105443','lexi-content-ref-2186351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-3105443','lexi-content-ref-2186351'])">Ref</a></span>): IV, IM:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Body Weight</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Postnatal Age</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Dose</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;">&lt;1 kg</p></td>
<td align="left">
<p style="text-indent:0em;">&lt;14 days</p></td>
<td align="left">
<p style="text-indent:0em;">30 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">14 to 28 days</p></td>
<td align="left">
<p style="text-indent:0em;">30 mg/kg/dose every 8 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">29 to 60 days</p></td>
<td align="left">
<p style="text-indent:0em;">30 mg/kg/dose every 6 hours</p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;">1 to ≤2 kg</p></td>
<td align="left">
<p style="text-indent:0em;">≤7 days</p></td>
<td align="left">
<p style="text-indent:0em;">30 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">8 to 28 days</p></td>
<td align="left">
<p style="text-indent:0em;">30 mg/kg/dose every 8 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">29 to 60 days</p></td>
<td align="left">
<p style="text-indent:0em;">30 mg/kg/dose every 6 hours</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">&gt;2 kg</p></td>
<td align="left">
<p style="text-indent:0em;">≤7 days</p></td>
<td align="left">
<p style="text-indent:0em;">30 mg/kg/dose every 8 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">8 to 60 days</p></td>
<td align="left">
<p style="text-indent:0em;">30 mg/kg/dose every 6 hours</p></td></tr></tbody></table></div>
<div class="block dop drugH1Div" id="F29768947"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b> Infants, Children, and Adolescents: IV, IM: 90 to 120 mg/kg/day in divided doses every 6 to 8 hours; maximum daily dose: 8 g/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2021'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1d1d4c54-ef98-486f-9c71-c0e9856532b2">Cystic fibrosis, acute pulmonary exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis <i>(Pseudomonas aeruginosa), </i>acute pulmonary exacerbation:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 200 to 300 mg/kg/day divided every 6 hours; maximum daily dose: 12 g/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3588112','lexi-content-ref-2512129','lexi-content-ref-22911974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3588112','lexi-content-ref-2512129','lexi-content-ref-22911974'])">Ref</a></span>). Administration of total daily dose by continuous infusion has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33315762','lexi-content-ref-18383117']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33315762','lexi-content-ref-18383117'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="02b4604f-7121-4a88-88dd-a5008cafb941">Intra-abdominal infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, complicated:</b> Infants, Children, and Adolescents: Limited data available in ages &lt;9 months: IV: 90 to 120 mg/kg/day in divided doses every 6 to 8 hours as part of an appropriate combination regimen; maximum dose: 2,000 mg/dose. Treatment duration varies based on specific source of infection, success of source control procedures, and clinical response; a total duration of 5 days is typically recommended in patients with adequate source control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28085573','lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28085573','lexi-content-ref-20034345'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="22b9b316-2e55-434d-884a-a716a70e536d">Meningitis or ventriculitis, health care-associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis or ventriculitis, healthcare-associated: </b>Limited data available: Infants, Children, and Adolescents: IV: 120 mg/kg/day in divided doses every 6 to 8 hours; doses up to 200 mg/kg/day divided every 6 hours have been reported in patients 2 to 18 years of age; maximum daily dose: 8 g/<b>day. </b>Duration of treatment varies based on isolated pathogen, cerebrospinal fluid studies, and clinical presentation; treat gram-negative pathogens for at least 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2731449','lexi-content-ref-2731448','lexi-content-ref-28203777','lexi-content-ref-2068463']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2731449','lexi-content-ref-2731448','lexi-content-ref-28203777','lexi-content-ref-2068463'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2f0164e-28ab-4d30-b893-da899a8afeac">Peritonitis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis (peritoneal dialysis), treatment:</b> Infants, Children, and Adolescents: Intraperitoneal: Continuous: Loading dose: 1,000 mg per liter of dialysate; maintenance dose: 250 mg per liter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis: </b>Children and Adolescents: IV: 30 mg/kg within 60 minutes before incision; may repeat in 4 hours for prolonged procedure or excessive blood loss; maximum dose: 2,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection: </b> Infants, Children, and Adolescents: Limited data available in ages &lt;9 months: IV: 90 to 120 mg/kg/day in divided doses every 6 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2731448','lexi-content-ref-3334567','lexi-content-ref-2682509','lexi-content-ref-3766490','lexi-content-ref-2731447']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2731448','lexi-content-ref-3334567','lexi-content-ref-2682509','lexi-content-ref-3766490','lexi-content-ref-2731447'])">Ref</a></span>). Treatment duration depends on age of patient, response to therapy, and extent of involvement; in patients ≥2 years of age, treatment duration may be as short as 3 to 5 days for uncomplicated cystitis or 6 to 10 days for pyelonephritis; patients &lt;2 years of age may require a longer course (eg, 7 to 14 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21873693','lexi-content-ref-31958969','lexi-content-ref-36009990','lexi-content-ref-29292282','lexi-content-ref-32364593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21873693','lexi-content-ref-31958969','lexi-content-ref-36009990','lexi-content-ref-29292282','lexi-content-ref-32364593'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51073356"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: IM, IV: The following adjustments have been recommended (Aronoff 2007). <b>Note:</b> Renally adjusted dose recommendations are based on doses of 90 to 120 mg/kg/day divided every 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR ≥30 mL/minute/1.73 m<sup>2</sup>: No adjustment required.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 15 to 20 mg/kg every 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 7.5 to 10 mg/kg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent hemodialysis: 7.5 to 10 mg/kg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Peritoneal dialysis (PD): 7.5 to 10 mg/kg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">CRRT: No adjustment required.</p></div>
<div class="block dohp drugH1Div" id="F51084479"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling. Use with caution (minor hepatic elimination occurs).</p></div>
<div class="block doa drugH1Div" id="F29768948"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="104068" href="/d/html/104068.html" rel="external">see "Aztreonam (systemic): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosing is presented based on the traditional infusion method over 30 minutes, unless otherwise specified as the extended infusion method over 3 hours (off-label method).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Use is generally reserved for patients with severe beta-lactam allergies; assess allergy and de-label if possible and/or consider beta-lactam desensitization. Clinical cross-reactivity can occur between aztreonam and ceftazidime; check skin testing before use in patients with ceftazidime allergy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36122788','lexi-content-ref-31826341','lexi-content-ref-29977963']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36122788','lexi-content-ref-31826341','lexi-content-ref-29977963'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f9ec9fd-fc1b-4a1f-868a-eeb97c396e6e">Bloodstream infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bloodstream infection (gram-negative bacteremia, including <i>P. aeruginosa</i>) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients who cannot use other beta-lactams (eg, penicillins, cephalosporins, carbapenems) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36122788']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36122788'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>); for empiric therapy in patients with sepsis or septic shock who are at risk for multidrug-resistant infection, give as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34605781']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34605781'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Duration of therapy:</i> Usual duration is 7 to 14 days depending on source, pathogen, extent of infection, and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moehring.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moehring.1'])">Ref</a></span>); a 7-day duration is recommended for patients with uncomplicated Enterobacterales infection who respond appropriately to antibiotic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29190320','lexi-content-ref-34738022','lexi-content-ref-30535100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29190320','lexi-content-ref-34738022','lexi-content-ref-30535100'])">Ref</a></span>). <b>Note:</b> If neutropenic, extend treatment until afebrile for 2 days and neutrophil recovery (ANC ≥500 cells/mm<sup>3</sup> and increasing) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21258094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21258094'])">Ref</a></span>). For <i>P. aeruginosa</i> bacteremia in patients with neutropenia, some experts treat for a minimum of 14 days and until recovery of neutrophils (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kanj.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kanj.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1d3e4522-e8bc-4496-b3e0-f1fcdd0f13d7">Diabetic foot infection, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic foot infection, moderate to severe (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients who cannot use other beta-lactams (eg, penicillins, cephalosporins, carbapenems) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36122788']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36122788'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 or 2 g every 8 hours as part of an appropriate combination regimen. Duration (which may include oral step-down therapy) is usually 2 to 4 weeks in the absence of osteomyelitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22619242','lexi-content-ref-14679443','lexi-content-ref-Weintrob.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22619242','lexi-content-ref-14679443','lexi-content-ref-Weintrob.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="312605aa-1bdc-4d1a-8d82-e9df83c1555c">Intra-abdominal infection, health care-associated or high-risk community-acquired infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, health care–associated or high-risk community-acquired infection (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients who cannot use other beta-lactams (eg, penicillins, cephalosporins, carbapenems). For community-acquired infection, reserve for severe infection or patients at high risk of adverse outcome and/or resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36122788','lexi-content-ref-Barshak.2018','lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36122788','lexi-content-ref-Barshak.2018','lexi-content-ref-20034345'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cholecystitis, acute uncomplicated:</i>
<b>IV:</b> 1 to 2 g every 8 hours as part of an appropriate combination; continue for 1 day after gallbladder removal or until clinical resolution in patients managed nonoperatively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29090866','lexi-content-ref-28085573','lexi-content-ref-20034345','lexi-content-ref-Vollmer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29090866','lexi-content-ref-28085573','lexi-content-ref-20034345','lexi-content-ref-Vollmer.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Other intra-abdominal infection (eg, cholangitis, complicated cholecystitis, appendicitis, diverticulitis, intra-abdominal abscess):</i>
<b> IV:</b> 1 to 2 g every 8 hours as part of an appropriate combination regimen. Total duration of therapy varies and may include transition to oral antibiotics: following adequate source control is 4 to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29090866','lexi-content-ref-25992746','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29090866','lexi-content-ref-25992746','lexi-content-ref-28085573'])">Ref</a></span>); for perforated appendicitis managed with appendectomy, 2 to 4 days may be sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36669519','lexi-content-ref-25992746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36669519','lexi-content-ref-25992746'])">Ref</a></span>). Without intervention, total duration is 7 to 10 days for appendicitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.2018','lexi-content-ref-Smink.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.2018','lexi-content-ref-Smink.1'])">Ref</a></span>) and 10 to 14 days for diverticulitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pemberton.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pemberton.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5330bca6-503f-4514-a8e2-2b7e43dcf6da">Intracranial abscess</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intracranial abscess (brain abscess) (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients who cannot use other beta-lactams (eg, penicillins, cephalosporins, carbapenems) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36122788','lexi-content-ref-Southwick.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36122788','lexi-content-ref-Southwick.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g every 6 to 8 hours as part of an appropriate combination regimen; duration generally ranges from 4 to 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29909695','lexi-content-ref-Southwick.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29909695','lexi-content-ref-Southwick.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90b4bed4-9c84-419c-9067-b0892c7eeb49">Meningitis, bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis, bacterial (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients who cannot use other beta-lactams (eg, penicillins, cephalosporins, carbapenems) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36122788','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36122788','lexi-content-ref-28203777'])">Ref</a></span>). As a component of empiric therapy for health care–associated infection or pathogen-specific therapy (eg, Enterobacteriaceae, <i>P. aeruginosa</i>, or<i> H. influenzae</i> beta-lactamase positive]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g every 6 to 8 hours; for empiric therapy, use in combination with vancomycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>). Treatment duration for gram-negative bacilli is a minimum of 10 to 14 days, although some experts recommend ≥21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28203777'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4040b928-ede0-41e5-be5a-45913fe112cc">Metallo-beta-lactamase-producing Enterobacterales and multidrug-resistant Stenotrophomonas maltophilia infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Metallo-beta-lactamase–producing Enterobacterales and multidrug-resistant <i>Stenotrophomonas maltophilia</i> infections (off-label use): IV: </b>2 g every 8 hours infused over 3 hours in combination with ceftazidime/avibactam (administered at the same time, if possible) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33870895','lexi-content-ref-32427286','lexi-content-ref-34864936','lexi-content-ref-35439291','lexi-content-ref-27551008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33870895','lexi-content-ref-32427286','lexi-content-ref-34864936','lexi-content-ref-35439291','lexi-content-ref-27551008'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a9d9ff41-d96a-4eb8-b9f5-e76594705fc3">Osteomyelitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteomyelitis (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve for patients who cannot use other beta-lactams (eg, penicillins, cephalosporins, carbapenems) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36122788','lexi-content-ref-26229122']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36122788','lexi-content-ref-26229122'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g every 8 hours for ≥6 weeks (including oral step-down therapy); for empiric therapy, use as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26229122','lexi-content-ref-Osmon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26229122','lexi-content-ref-Osmon.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2f0164e-28ab-4d30-b893-da899a8afeac">Peritonitis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis, treatment (peritoneal dialysis) (alternative agent) (off-label route):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients who cannot use other beta-lactams (eg, penicillins, cephalosporins, carbapenems) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36122788']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36122788'])">Ref</a></span>). Intraperitoneal administration is preferred to IV administration unless the patient has sepsis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35264029']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35264029'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intermittent:</i>
<b>Intraperitoneal:</b> 2 g added to the dialysate solution once daily; allow to dwell ≥6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2488380','lexi-content-ref-35264029']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2488380','lexi-content-ref-35264029'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuous (with every exchange):</i>
<b>Intraperitoneal:</b> Loading dose: 500 mg to 1 g/L of dialysate added to first dialysate exchange; maintenance dose: 250 mg/L of dialysate with each subsequent dialysate exchange (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Burkart.1','lexi-content-ref-2068475','lexi-content-ref-6542606','lexi-content-ref-35264029']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Burkart.1','lexi-content-ref-2068475','lexi-content-ref-6542606','lexi-content-ref-35264029'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of therapy:</i> ≥3 weeks for patients with adequate clinical response; for patients with no improvement after 5 days, remove catheter and treat with appropriate systemic antibiotics for 14 days after catheter removal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35264029']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35264029'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7792e77c-7758-4230-a81e-dc7dd3a6acb9">Pneumonia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients who cannot use other beta-lactams (eg, penicillins, cephalosporins, carbapenems) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36122788','lexi-content-ref-27418577','lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36122788','lexi-content-ref-27418577','lexi-content-ref-31573350'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Community-acquired pneumonia: </i></b>For empiric therapy of inpatients at risk of infection with a gram-negative pathogen(s), including<i> P. aeruginosa:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 2 g every 8 hours as part of an appropriate combination regimen. Total duration (which may include oral step-down therapy) is a minimum of 5 days; a longer course may be required for patients with an immunocompromising condition, severe or complicated infection, or for <i>P. aeruginosa </i>infection. Patients should be clinically stable with normal vital signs prior to discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-File.1','lexi-content-ref-31573350','lexi-content-ref-32561442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-File.1','lexi-content-ref-31573350','lexi-content-ref-32561442'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Hospital-acquired or ventilator-associated pneumonia:</i></b> For empiric therapy or pathogen-specific therapy of gram-negative pathogen(s), including <i>P. aeruginosa</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 2 g every 8 hours; when used for empiric therapy, give as part of an appropriate combination regimen. Duration of therapy varies based on disease severity and response to therapy; treatment is typically given for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27418577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27418577'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5389b037-d8ce-48e2-98b3-f8bb5a208a34">Skin and soft tissue infection, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection, moderate to severe (alternate agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients who cannot use other beta-lactams (eg, penicillins, cephalosporins, carbapenems) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36122788']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36122788'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 or 2 g every 8 hours; for empiric therapy, use as part of an appropriate combination regimen. Usual duration (including oral step-down therapy) is 5 to 14 days based on severity and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27585969','lexi-content-ref-Kanj.2','lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27585969','lexi-content-ref-Kanj.2','lexi-content-ref-Spelman.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical (perioperative) prophylaxis (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for procedures that warrant gram-negative coverage in patients who cannot use other beta-lactams (eg, penicillins, cephalosporins, carbapenems) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36122788','lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36122788','lexi-content-ref-23327981'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g within 60 minutes prior to surgical incision, as part of an appropriate combination regimen. Doses may be repeated in 4 hours if procedure is lengthy or if there is excessive blood loss (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>). In cases where an extension of prophylaxis is warranted postoperatively, total duration should be ≤24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24799638']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24799638'])">Ref</a></span>). Postoperative prophylaxis is not recommended in clean and clean-contaminated surgeries (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28467526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28467526'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3dbb92e-1e0f-40e8-92cb-d0cf047a674d">Urinary tract infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve for patients who cannot use other beta-lactams (eg, penicillins, cephalosporins, carbapenems) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36122788','lexi-content-ref-31608743']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36122788','lexi-content-ref-31608743'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 to 2 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31608743','lexi-content-ref-3909336','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31608743','lexi-content-ref-3909336','lexi-content-ref-manu.1'])">Ref</a></span>). Switch to an appropriate oral regimen once symptoms improve if culture and susceptibility results allow (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31608743']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31608743'])">Ref</a></span>). Total duration of therapy ranges from 5 to 14 days; for patients with symptomatic improvement within the first 48 to 72 hours of therapy, some experts recommend shorter courses of 7 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gupta.1','lexi-content-ref-21292654','lexi-content-ref-30535100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gupta.1','lexi-content-ref-21292654','lexi-content-ref-30535100'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991710"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption>
<b>Aztreonam Dosage Adjustments for Altered Kidney Function<sup>a</sup>: IV, IM<sup>b</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">CrCl<sup>c</sup> (mL/minute)</p></th>
<th align="center">
<p style="text-indent:0em;">If the usual recommended dose is 1 g every 8 hours</p></th>
<th align="center">
<p style="text-indent:0em;">If the usual recommended dose is 2 g every 6 or 8 hours</p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Recommendations are expert opinion derived from: Fillastre 1985; Gerig 1984; Gross 2018; Mihindu 1983; Xu 2017; manufacturer's labeling.</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<sup>b </sup>Doses &gt;1 g should be given IV.</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<sup>c</sup> Calculated using the Cockcroft-Gault equation.</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<sup>d</sup> A reduced dose while maintaining the frequency may be preferred in severe infections (Xu 2017), although maintaining the dose but prolonging the dosing interval has been described (Fillastre 1985; Mihindu 1983) and is utilized by some centers.</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<sup>e </sup>Dialyzable (~30% to 60% with low flux dialyzers [Fillastre 1985; Gerig 1984]); when scheduled dose falls on a dialysis day, administer after hemodialysis (Gross 2018).</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">30 to &lt;130</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">10 to &lt;30<sup>d</sup></p></td>
<td align="center">
<p style="text-indent:0em;">1 g every 12 hours <b>or</b></p>
<p style="text-indent:0em;">1 g as a single dose then 500 mg every 8 hours</p></td>
<td align="center">
<p style="text-indent:0em;">2 g every 12 hours <b>or</b></p>
<p style="text-indent:0em;">2 g as a single dose then 1 g every 6 or 8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;10<sup>d</sup></p></td>
<td align="center">
<p style="text-indent:0em;">1 g every 24 hours <b>or</b></p>
<p style="text-indent:0em;">1 g as a single dose then 250 mg every 8 hours</p></td>
<td align="center">
<p style="text-indent:0em;">2 g every 24 hours <b>or</b></p>
<p style="text-indent:0em;">2 g as a single dose then 500 mg every 6 or 8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hemodialysis, intermittent (thrice weekly)<sup>e</sup></p></td>
<td align="center">
<p style="text-indent:0em;">1 g every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">2 g every 24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Peritoneal dialysis</p></td>
<td align="center">
<p style="text-indent:0em;">1 g every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">2 g every 24 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post-trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> If usual recommended dose is 2 g every 6 to 8 hours: 2 g every 6 hours (Xu 2017; expert opinion). Consider prolonging the infusion time to over 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29290748','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29290748','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g as a single dose followed by 1 g every 8 hours or 2 g every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g as a single dose followed by 1 to 2 g every 12 hours. Ensure at least 1 dose is infused after PIRRT session ends on PIRRT days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989031"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution (minor hepatic elimination occurs).</p></div>
<div class="block adr drugH1Div" id="F29768914"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia (children 3% to 11%; adults &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (children, high dose: &gt;3 times ULN: 15% to 20%; children, standard dose: increased serum AST 4%, increased serum ALT 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site (children 12%, adults 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Phlebitis (intravenous: ≤2%), thrombophlebitis (intravenous: ≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (children 4%, adults ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (≤1%), nausea (≤1%), vomiting (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia (children 6%, adults &lt;1%), thrombocythemia (children 4%, adults &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (intravenous: Children 3%, adults &lt;1%), discomfort at injection site (intramuscular: ≤2%), swelling at injection site (intramuscular: ≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (children 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (≤1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abdominal cramps, anaphylaxis, anemia, angioedema, breast tenderness, bronchospasm, chest pain, <i>Clostridioides difficile</i>–associated diarrhea, confusion, diaphoresis, diplopia, dizziness, dysgeusia, dyspnea, erythema multiforme, exfoliative dermatitis, flushing, gastrointestinal hemorrhage, halitosis, headache, hepatitis, hepatobiliary disease, hypotension, increased serum alkaline phosphatase, increased serum ALT (adults), increased serum AST (adults), induration at injection site, insomnia, jaundice, leukocytosis, malaise, myalgia, nasal congestion, numbness of tongue, oral mucosa ulcer, pancytopenia, paresthesia, petechia, positive direct Coombs test, prolonged partial thromboplastin time, prolonged prothrombin time, pruritus, pseudomembranous colitis, purpura, seizure, sneezing, thrombocytopenia, tinnitus, toxic epidermal necrolysis, urticaria, vaginitis, ventricular bigeminy (transient), ventricular premature contractions (transient), vertigo, vulvovaginal candidiasis, weakness, wheezing</p></div>
<div class="block coi drugH1Div" id="F29768911"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to aztreonam or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F29768912"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Beta-lactam allergy: Rare cross-allergenicity to penicillins, cephalosporins, or carbapenems may occur; use with caution in patients with a history of hypersensitivity to beta-lactams.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosing adjustment required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow transplantation: Use with caution in patients undergoing bone marrow transplant with multiple risk factors for toxic epidermal necrolysis (TEN) (eg, sepsis, radiation therapy, drugs known to cause TEN); rare cases of TEN in this population have been reported.</p></div>
<div class="block foc drugH1Div" id="F29768966"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Azactam: 1 g (1 ea); 2 g (1 ea) [sodium free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea); 2 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F29768893"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F29768968"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Azactam Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $35.67</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g (per each): $71.34</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Aztreonam Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $32.77 - $43.30</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g (per each): $65.54 - $87.97</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52614614"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: IV route is preferred for doses &gt;1,000 mg or in patients with severe life-threatening infections. Administer by IVP over 3 to 5 minutes or by intermittent infusion over 20 to 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>). For continuous infusion, infuse daily dose over 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33315762','lexi-content-ref-18383117']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33315762','lexi-content-ref-18383117'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Administer by deep IM injection into a large muscle mass such as the upper outer quadrant of the gluteus maximus or lateral part of the thigh. Doses &gt;1,000 mg should be administered IV. Do not mix with any local anesthetic agent.</p></div>
<div class="block adm drugH1Div" id="F29768952"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Doses &gt;1 g should be administered IV.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> Administer by deep injection into large muscle mass, such as upper outer quadrant of gluteus maximus or the lateral part of the thigh.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Administer by slow IV push over 3 to 5 minutes or by intermittent infusion over 20 to 60 minutes. For extended infusion administration (off-label method), administer over 3 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27025644','lexi-content-ref-27132188']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27025644','lexi-content-ref-27132188'])">Ref</a></span>) or 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29290748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29290748'])">Ref</a></span>); some experts prefer administration over 3 hours for infections caused by carbapenem-resistant Enterobacterales or <i>S. maltophilia </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34864936','lexi-content-ref-35439291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34864936','lexi-content-ref-35439291'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F29768927"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Prior to reconstitution, store intact vials at room temperature; avoid excessive heat.</p>
<p style="text-indent:-2em;margin-left:2em;">Stability in solution:</p>
<p style="text-indent:-2em;margin-left:4em;">≤20 mg/mL (<b>for IV infusion</b>): After dilution to a final concentration of ≤20 mg/mL in D5W, LR, NS, or other appropriate solution, should be used within 48 hours if stored at room temperature or within 7 days if refrigerated.</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;20 mg/mL:</p>
<p style="text-indent:-2em;margin-left:6em;">Reconstituted in SWFI (<b>IM or IV bolus injection</b>) or NS (<b>IM only</b>): Should be used within 48 hours if stored at room temperature or within 7 days if refrigerated.</p>
<p style="text-indent:-2em;margin-left:6em;">Reconstituted in sterile bacteriostatic water for injection (with benzyl alcohol or with methyl- and propylparabens) or bacteriostatic sodium chloride injection (with benzyl alcohol) (<b>IM only</b>): Use immediately after preparation.</p></div>
<div class="block usep drugH1Div" id="F53571278"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of urinary tract infections, lower respiratory tract infections, intra-abdominal infections, skin and soft tissue infections, and gynecological infections caused by susceptible organisms (FDA approved in ages ≥9 months and adults); treatment of bacteremia (FDA approved in adults); has also been used for the treatment of peritonitis in patients with peritoneal catheters. <b>Note: </b>Aztreonam is not approved for use in skin and soft tissue infections in pediatric patients if the infection is known or suspected to be caused by <i>Haemophilus influenzae</i> type b.</p></div>
<div class="block mst drugH1Div" id="F29768883"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Aztreonam may be confused with azidothymidine</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F29768921"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F29768918"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F29768907"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Aztreonam crosses the placenta and can be detected in the fetus.</p>
<p style="text-indent:0em;margin-top:2em;">Information related to aztreonam for the treatment of urinary tract infections in pregnancy is limited. Use may be considered in pregnant patients allergic to preferred antibiotics (Glaser 2015; Jolley 2010).</p></div>
<div class="block mopp drugH1Div" id="F53571279"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal and hepatic function tests; monitor for stool frequency; monitor for signs of hypersensitivity, including anaphylaxis.</p></div>
<div class="block pha drugH1Div" id="F29768931"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested. Monobactam structure makes cross-allergenicity with beta-lactams unlikely.</p></div>
<div class="block phk drugH1Div" id="F29768933"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: IM: Well absorbed; IM and IV doses produce comparable serum concentrations.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely into body tissues, cerebrospinal fluid, bronchial secretions, peritoneal fluid, bile, and bone.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates:</p>
<p style="text-indent:-2em;margin-left:8em;">PNA &lt;7 days:</p>
<p style="text-indent:-2em;margin-left:10em;">Weight &lt;2,500 g: ~0.36 to 0.58 L/kg (Likitnukul 1987; Stutman 1984).</p>
<p style="text-indent:-2em;margin-left:10em;">Weight &gt;2,500 g: 0.26 L/kg (Stutman 1984).</p>
<p style="text-indent:-2em;margin-left:8em;">PNA ≥7 days: 0.3 L/kg (Stutman 1984).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: 0.2 to 0.29 L/kg (Stutman 1984).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 0.15 to 0.18 L/kg (Brogden 1986).</p>
<p style="text-indent:-2em;margin-left:4em;">Relative diffusion of antimicrobial agents from blood into CSF: Good only with inflammation (exceeds usual MICs).</p>
<p style="text-indent:-2em;margin-left:4em;">CSF:blood level ratio: Meninges: Inflamed: 8% to 40%; Normal: ~1%.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 56%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (minor %).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates:</p>
<p style="text-indent:-2em;margin-left:6em;">PNA &lt;7 days:</p>
<p style="text-indent:-2em;margin-left:8em;">Weight &lt;2,500 g: ~5.7 hours (Stutman 1984).</p>
<p style="text-indent:-2em;margin-left:8em;">Weight &gt;2,500 g: ~2.6 hours (Stutman 1984).</p>
<p style="text-indent:-2em;margin-left:6em;">PNA ≥7 days: ~2.4 hours (Stutman 1984).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;12 years: ~1.7 hours (Stutman 1984).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥10 years and Adolescents with cystic fibrosis: 1.3 hours (Reed 1986).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Normal renal function: 1.5 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease: 6 to 8.4 hours (Brogden 1986).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: IM: Within 60 minutes (Mattie 1988).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (60% to 70% as unchanged drug); feces (~12%).</p></div>
<div class="block phksp drugH1Div" id="F51153954"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Serum half-life is prolonged.</p>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i> Time dependent, associated with time free drug concentration (<i>f</i>T) &gt; minimum inhibitory concentration (MIC) and AUC<sub>24</sub> to MIC ratio:</p>
<p style="text-indent:-2em;margin-left:6em;">Organism specific:</p>
<p style="text-indent:-2em;margin-left:8em;">Gram-negative organisms (eg,<i> E. coli</i>, <i>P. aeruginosa</i>): Goal: 50% to 60% <i>f</i>T &gt; MIC (bacteriostatic); ≥65% <i>f</i>T &gt; MIC (bactericidal) (Crandon 2013; Ramsey 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">Expected drug exposure in normal renal function:</p>
<p style="text-indent:-2em;margin-left:6em;">Pediatric patients: C<sub>max </sub>(peak): 30 mg/kg (3-minute infusion), single dose: IV:</p>
<p style="text-indent:-2em;margin-left:8em;">Neonates &lt;1 week of age, &lt;2.5 kg: 83 ± 21.3 mg/L (Stutman 1984).</p>
<p style="text-indent:-2em;margin-left:8em;">Neonates &lt;1 week of age, &gt;2.5 kg: 97.8 ± 5 mg/L (Stutman 1984).</p>
<p style="text-indent:-2em;margin-left:8em;">Neonates ≥1 week to 1 month of age: 97.4 ± 4.3 mg/L (Stutman 1984).</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and children ≤2 years of age: 118.7 ± 6.7 mg/L (Stutman 1984).</p>
<p style="text-indent:-2em;margin-left:8em;">Children &gt;2 to 12 years of age: 96.9 ± 16.2 mg/L (Stutman 1984).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: C<sub>max </sub>(peak): Single dose (30-minute infusion): IV:</p>
<p style="text-indent:-2em;margin-left:8em;">500 mg: 54 mg/L.</p>
<p style="text-indent:-2em;margin-left:8em;">1 g: 90 mg/L.</p>
<p style="text-indent:-2em;margin-left:8em;">2 g: 204 mg/L.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>Generally little to no postantibiotic effect (&lt;1 hour) for gram-negative bacilli (including <i>P. aeruginosa</i>) (Hanberger 1990; Ramsey 2016).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31958969">
<a name="31958969"></a>Afolabi TM, Goodlet KJ, Fairman KA. Association of antibiotic treatment duration with recurrence of uncomplicated urinary tract infection in pediatric patients. <i>Ann Pharmacother</i>. 2020;54(8):757-766. doi:10.1177/1060028019900650<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/31958969/pubmed" id="31958969" target="_blank">31958969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2021">
<a name="AAP.2021"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21873693">
<a name="21873693"></a>American Academy of Pediatrics (AAP) Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management, Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. <i>Pediatrics</i>. 2011;128(3):595-610.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/21873693/pubmed" id="21873693" target="_blank">21873693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29794678">
<a name="29794678"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 195: prevention of infection after gynecologic procedures. <i>Obstet Gynecol</i>. 2018;131(6):e172-e189.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/29794678/pubmed" id="29794678" target="_blank">29794678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24799638">
<a name="24799638"></a>Anderson DJ, Podgorny K, Berríos-Torres SI, et al. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. <i>Infect Control Hosp Epidemiol</i>. 2014;35(6):605-627. doi:10.1086/676022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/24799638/pubmed" id="24799638" target="_blank">24799638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36009990">
<a name="36009990"></a>Autore G, Bernardi L, La Scola C, et al. Management of pediatric urinary tract infections: a Delphi study. <i>Antibiotics (Basel)</i>. 2022;11(8):1122. doi:10.3390/antibiotics11081122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/36009990/pubmed" id="36009990" target="_blank">36009990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2731449">
<a name="2731449"></a>Ayroza-Galvão PA, Milstein-Kuschnaroff TM, Mimica IM, et al. Aztreonam in the treatment of bacterial meningitis. <i>Chemotherapy</i>. 1989;35(suppl 1):S39-S44. doi:10.1159/000238719<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/2731449/pubmed" id="2731449" target="_blank">2731449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Azactam.1">
<a name="Azactam.1"></a>Azactam (aztreonam) injection, USP [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31608743">
<a name="31608743"></a>Bader MS, Loeb M, Leto D, Brooks AA. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. <i>Postgrad</i>
<i>Med</i>. 2020;132(3):234-250. doi:10.1080/00325481.2019.1680052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/31608743/pubmed" id="31608743" target="_blank">31608743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29292282">
<a name="29292282"></a>Balighian E, Burke M. Urinary tract infections in children. <i>Pediatr Rev</i>. 2018;39(1):3-12. doi:10.1542/pir.2017-0007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/29292282/pubmed" id="29292282" target="_blank">29292282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barshak.2018">
<a name="Barshak.2018"></a>Barshak MB. Antimicrobial approach to intra-abdominal infections in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26229122">
<a name="26229122"></a>Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/26229122/pubmed" id="26229122" target="_blank">26229122</a>]</span>
<span class="doi">10.1093/cid/civ482</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28467526">
<a name="28467526"></a>Berríos-Torres SI, Umscheid CA, Bratzler DW, et al; Healthcare Infection Control Practices Advisory Committee. Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017. <i>JAMA Surg</i>. 2017;152(8):784-791. doi:10.1001/jamasurg.2017.0904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/28467526/pubmed" id="28467526" target="_blank">28467526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet.</i> 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29909695">
<a name="29909695"></a>Bodilsen J, Brouwer MC, Nielsen H, Van De Beek D. Anti-infective treatment of brain abscess. <i>Expert Rev Anti Infect Ther</i>. 2018;16(7):565-578. doi:10.1080/14787210.2018.1489722<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/29909695/pubmed" id="29909695" target="_blank">29909695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3588112">
<a name="3588112"></a>Bosso JA, Black PG, Matsen JM. Efficacy of aztreonam in pulmonary exacerbations of cystic fibrosis. <i>Pediatr Infect Dis J</i>. 1987;6(4):393-397. doi:10.1097/00006454-198704000-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/3588112/pubmed" id="3588112" target="_blank">3588112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 28th ed. American Academy of Pediatrics; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23327981">
<a name="23327981"></a>Bratzler DW, Dellinger EP, Olsen KM, et al, “Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,” <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/23327981/pubmed" id="23327981" target="_blank">23327981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3512234">
<a name="3512234"></a>Brogden RN, Heel RC. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. <i>Drugs</i>. 1986;31(2):96-130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/3512234/pubmed" id="3512234" target="_blank">3512234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Burkart.1">
<a name="Burkart.1"></a>Burkart JM. Microbiology and therapy of peritonitis in peritoneal dialysis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31826341">
<a name="31826341"></a>Castells M, Khan DA, Phillips EJ. Penicillin allergy. <i>N Engl J Med</i>. 2019;381(24):2338-2351. doi:10.1056/NEJMra1807761<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/31826341/pubmed" id="31826341" target="_blank">31826341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29977963">
<a name="29977963"></a>Chen JR, Tarver SA, Alvarez KS, Wei W, Khan DA. Improving aztreonam stewardship and cost through a penicillin allergy testing clinical guideline.<i> Open Forum Infect Dis</i>. 2018;5(6):ofy106. doi:10.1093/ofid/ofy106<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/29977963/pubmed" id="29977963" target="_blank">29977963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29190320">
<a name="29190320"></a>Chotiprasitsakul D, Han JH, Cosgrove SE, et al; Antibacterial Resistance Leadership Group. Comparing the outcomes of adults with enterobacteriaceae bacteremia receiving short-course versus prolonged-course antibiotic therapy in a multicenter, propensity score-matched cohort. <i>Clin Infect Dis</i>. 2018;66(2):172-177. doi:10.1093/cid/cix767<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/29190320/pubmed" id="29190320" target="_blank">29190320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29290748">
<a name="29290748"></a>Cies JJ, LaCoursiere RJ, Moore WS 2nd, Chopra A. Therapeutic drug monitoring of prolonged infusion aztreonam for multi-drug resistant Pseudomonas aeruginosa: a case report. <i>J Pediatr Pharmacol Ther.</i> 2017;22(6):467-470. doi:10.5863/1551-6776-22.6.467<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/29290748/pubmed" id="29290748" target="_blank">29290748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33315762">
<a name="33315762"></a>Cowart MC, Ferguson CL. Optimization of aztreonam in combination with ceftazidime/avibactam in a cystic fibrosis patient with chronic Stenotrophomonas maltophilia pneumonia using therapeutic drug monitoring: A case study. <i>Ther Drug Monit</i>. 2021;43(2):146-149. doi:10.1097/FTD.0000000000000857<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/33315762/pubmed" id="33315762" target="_blank">33315762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23650162">
<a name="23650162"></a>Crandon JL, Nicolau DP. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers. <i>Antimicrob Agents Chemother.</i> 2013;57(7):3299-3306. doi:10.1128/AAC.01989-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/23650162/pubmed" id="23650162" target="_blank">23650162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4039189">
<a name="4039189"></a>Creasey WA, Platt TB, Frantz M, et al, “Pharmacokinetics of Aztreonam in Elderly Male Volunteers,” <i>Br J Clin Pharmacol</i>, 1985, 19:233-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/4039189/pubmed" id="4039189" target="_blank">4039189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36669519">
<a name="36669519"></a>de Wijkerslooth EML, Boerma EG, van Rossem CC, et al; APPIC Study Group. 2 days versus 5 days of postoperative antibiotics for complex appendicitis: a pragmatic, open-label, multicentre, non-inferiority randomised trial. <i>Lancet</i>. 2023;401(10374):366-376. doi:10.1016/S0140-6736(22)02588-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/36669519/pubmed" id="36669519" target="_blank">36669519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33870895">
<a name="33870895"></a>Diarra A, Pascal L, Carpentier B, et al. Successful use of avibactam and aztreonam combination for a multiresistant Stenotrophomonas maltophilia bloodstream infection in a patient with idiopathic medullary aplasia.<i> Infect Dis Now.</i> 2021;51(7):637-638. doi:10.1016/j.idnow.2021.01.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/33870895/pubmed" id="33870895" target="_blank">33870895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2068475">
<a name="2068475"></a>Dratwa M, Glupczynski Y, Lameire N, et al. Treatment of gram-negative peritonitis with aztreonam in patients undergoing continuous ambulatory peritoneal dialysis. <i>Rev Infect Dis</i>. 1991;13(suppl 7):S645-S647. doi:10.1093/clinids/13.supplement_7.s645<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/2068475/pubmed" id="2068475" target="_blank">2068475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27585969">
<a name="27585969"></a>Dryden M, Zhang Y, Wilson D, Iaconis JP, Gonzalez J. A phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities. <i>J Antimicrob Chemother</i>. 2016;71(12):3575-3584. doi:10.1093/jac/dkw333<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/27585969/pubmed" id="27585969" target="_blank">27585969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34605781">
<a name="34605781"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. <i>Crit Care Med</i>. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/34605781/pubmed" id="34605781" target="_blank">34605781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32427286">
<a name="32427286"></a>Falcone M, Daikos GL, Tiseo G, et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by Metallo-β-lactamase-producing enterobacterales. <i>Clin Infect Dis</i>. 2021;72(11):1871-1878. doi:10.1093/cid/ciaa586<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/32427286/pubmed" id="32427286" target="_blank">32427286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2731448">
<a name="2731448"></a>Feris J, Moledina N, Rodriguez WJ, et al. Aztreonam in the treatment of gram-negative meningitis and other gram-negative infections. <i>Chemotherapy</i>. 1989;35(suppl 1):S31-S38. doi:10.1159/000238718<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/2731448/pubmed" id="2731448" target="_blank">2731448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-File.1">
<a name="File.1"></a>File TM. Treatment of community-acquired pneumonia in adults who require hospitalization. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4038635">
<a name="4038635"></a>Fillastre JP, Leroy A, Baudoin C, et al. Pharmacokinetics of aztreonam in patients with chronic renal failure. <i>Clin Pharmacokinet.</i> 1985;10(1):91-100. doi:10.2165/00003088-198510010-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/4038635/pubmed" id="4038635" target="_blank">4038635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32364593">
<a name="32364593"></a>Fox MT, Amoah J, Hsu AJ, Herzke CA, Gerber JS, Tamma PD. Comparative effectiveness of antibiotic treatment duration in children with pyelonephritis. <i>JAMA Netw Open</i>. 2020;3(5):e203951. doi:10.1001/jamanetworkopen.2020.3951<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/32364593/pubmed" id="32364593" target="_blank">32364593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21258094">
<a name="21258094"></a>Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;52(4):e56-e93. doi:10.1093/cid/cir073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/21258094/pubmed" id="21258094" target="_blank">21258094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2488380">
<a name="2488380"></a>Fuiano G, Sepe V, Viscione M, Nani E, Conte G. Effectiveness of single daily intraperitoneal administration of aztreonam and cefuroxime in the treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD). <i>Perit Dial Int</i>. 1989;9(4):273-275.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/2488380/pubmed" id="2488380" target="_blank">2488380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6542606">
<a name="6542606"></a>Gerig JS, Bolton ND, Swabb EA, Scheld WM, Bolton WK. Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics. <i>Kidney Int</i>. 1984;26(3):308-318. doi:10.1038/ki.1984.174<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/6542606/pubmed" id="6542606" target="_blank">6542606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26475951">
<a name="26475951"></a>Glaser AP, Schaeffer AJ. Urinary tract infection and bacteriuria in pregnancy. <i>Urol Clin North Am</i>. 2015;42(4):547-560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/26475951/pubmed" id="26475951" target="_blank">26475951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29090866">
<a name="29090866"></a>Gomi H, Solomkin JS, Schlossberg D, et al. Tokyo guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. <i>J Hepatobiliary Pancreat Sci.</i> 2018;25(1):3-16. doi:10.1002/jhbp.518<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/29090866/pubmed" id="29090866" target="_blank">29090866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30150467">
<a name="30150467"></a>Gross AE, Xu H, Zhou D, Al-Huniti N. Simplified aztreonam dosing in patients with end-stage renal disease: results of a Monte Carlo simulation.<i> Antimicrob Agents Chemother.</i> 2018;62(11):e01066-18. doi:10.1128/AAC.01066-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/30150467/pubmed" id="30150467" target="_blank">30150467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gupta.1">
<a name="Gupta.1"></a>Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2183707">
<a name="2183707"></a>Hanberger H, Nilsson LE, Kihlström E, Maller R. Postantibiotic effect of beta-lactam antibiotics on Escherichia coli evaluated by bioluminescence assay of bacterial ATP. <i>Antimicrob Agents Chemother.</i> 1990;34(1):102-106. doi:10.1128/aac.34.1.102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/2183707/pubmed" id="2183707" target="_blank">2183707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18383117">
<a name="18383117"></a>Hayes D Jr, Kanga JF, Anstead MI, Kuhn RJ. Novel approach to the eradication of <i>Pseudomonas aeruginosa</i> in an infant with CF after outpatient treatment failure. <i>Pediatr Pulmonol</i>. 2008;43(5):511-513. doi:10.1002/ppul.20791<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/18383117/pubmed" id="18383117" target="_blank">18383117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34738022">
<a name="34738022"></a>Heil EL, Bork JT, Abbo LM, et al. Optimizing the management of uncomplicated gram-negative bloodstream infections: consensus guidance using a modified delphi process. <i>Open Forum Infect Dis</i>. 2021;8(10):ofab434. doi:10.1093/ofid/ofab434<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/34738022/pubmed" id="34738022" target="_blank">34738022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy</i>. 2009;29(5):562-77. doi: 10.1592/phco.29.5.562<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3334567">
<a name="3334567"></a>Kafetzis D, Papadimitriou G, Stavridis C, Sinaniotis C, Papoulias G. Treatment of pyelonephritis with aztreonam: kinetic study in children. <i>Chemioterapia</i>. 1987;6(2)(suppl):284-285.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/3334567/pubmed" id="3334567" target="_blank">3334567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27418577">
<a name="27418577"></a>Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clin Infect Dis</i>. 2016;63(5):e61-e111. doi: 10.1093/cid/ciw353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/27418577/pubmed" id="27418577" target="_blank">27418577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kanj.1">
<a name="Kanj.1"></a>Kanj SS, Sexton DJ. Pseudomonas aeruginosa bacteremia and endocarditis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 4, 2023a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kanj.2">
<a name="Kanj.2"></a>Kanj SS, Sexton DJ. Pseudomonas aeruginosa skin and soft tissue infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 5, 2023b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36122788">
<a name="36122788"></a>Khan DA, Banerji A, Blumenthal KG, et al. Drug allergy: a 2022 practice parameter update. <i>J Allergy Clin Immunol.</i> 2022;150(6):1333-1393. doi:10.1016/j.jaci.2022.08.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/36122788/pubmed" id="36122788" target="_blank">36122788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2682509">
<a name="2682509"></a>Kline MW. The role of aztreonam in treatment of complicated urinary tract infections in children. <i>Pediatr Infect Dis J</i>. 1989;8(9)(suppl):S113-S132. doi:10.1097/00006454-198909001-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/2682509/pubmed" id="2682509" target="_blank">2682509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2068463">
<a name="2068463"></a>Lentnek AL, Williams RR. Aztreonam in the treatment of gram-negative bacterial meningitis. <i>Rev Infect Dis</i>. 1991;13(suppl 7):S586-S590. doi:10.1093/clinids/13.supplement_7.s586<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/2068463/pubmed" id="2068463" target="_blank">2068463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3105443">
<a name="3105443"></a>Likitnukul S, McCracken GH Jr, Threlkeld N, Darabi A, Olsen K. Pharmacokinetics and plasma bactericidal activity of aztreonam in low-birth-weight infants. <i>Antimicrob Agents Chemother</i>. 1987;31(1):81-83. doi:10.1128/AAC.31.1.81<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/3105443/pubmed" id="3105443" target="_blank">3105443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35264029">
<a name="35264029"></a>Li PK, Chow KM, Cho Y, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. <i>Peritoneal Dialysis International. </i>2022;42(2):110-153. doi:10.1177/08968608221080586<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/35264029/pubmed" id="35264029" target="_blank">35264029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22619242">
<a name="22619242"></a>Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. <i>Clin Infect Dis</i>. 2012;54(12):e132-e173. doi:10.1093/cid/cis346<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/22619242/pubmed" id="22619242" target="_blank">22619242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14679443">
<a name="14679443"></a>Lipsky BA, Itani K, Norden C; Linezolid Diabetic Foot Infections Study Group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. <i>Clin Infect Dis</i>. 2004;38(1):17-24. doi:10.1086/380449<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/14679443/pubmed" id="14679443" target="_blank">14679443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3286083">
<a name="3286083"></a>Mattie H. Clinical pharmacokinetics of aztreonam. <i>Clin Pharmacokinet</i>. 1988;14(3):148-155. doi: 10.2165/00003088-198814030-00003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/3286083/pubmed" id="3286083" target="_blank">3286083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society (SIS) revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;18(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Resp Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6685452">
<a name="6685452"></a>Mihindu JC, Scheld WM, Bolton ND, Spyker DA, Swabb EA, Bolton WK. Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction. <i>Antimicrob Agents Chemother.</i> 1983;24(2):252-261. doi:10.1128/AAC.24.2.252<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/6685452/pubmed" id="6685452" target="_blank">6685452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moehring.1">
<a name="Moehring.1"></a>Moehring R, Anderson DJ. Gram-negative bacillary bacteremia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27551008">
<a name="27551008"></a>Mojica MF, Ouellette CP, Leber A, et al. Successful treatment of bloodstream infection due to metallo-β-lactamase-producing Stenotrophomonas maltophilia in a renal transplant patient. <i>Antimicrob Agents Chemother</i>. 2016;60(9):5130-5134. doi:10.1128/AAC.00264-16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/27551008/pubmed" id="27551008" target="_blank">27551008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Osmon.1">
<a name="Osmon.1"></a>Osmon DR, Tande AJ. Nonvertebral osteomyelitis in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 21, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pemberton.2020">
<a name="Pemberton.2020"></a>Pemberton JH. Acute colonic diverticulitis: medical management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32561442">
<a name="32561442"></a>Ramirez JA, Musher DM, Evans SE, et al. Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies. <i>Chest</i>. 2020;158(5):1896-1911. doi:10.1016/j.chest.2020.05.598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/32561442/pubmed" id="32561442" target="_blank">32561442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27334663">
<a name="27334663"></a>Ramsey C, MacGowan AP. A review of the pharmacokinetics and pharmacodynamics of aztreonam. <i>J Antimicrob Chemother.</i> 2016;71(10):2704-2712. doi:10.1093/jac/dkw231<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/27334663/pubmed" id="27334663" target="_blank">27334663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3774385">
<a name="3774385"></a>Reed MD, Aronoff SC, Stern RC, et al. Single-dose pharmacokinetics of aztreonam in children with cystic fibrosis. <i>Pediatr Pulmonol</i>. 1986;2(5):282-286. doi:10.1002/ppul.1950020506<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/3774385/pubmed" id="3774385" target="_blank">3774385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992746">
<a name="25992746"></a>Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. <i>N Engl J Med.</i> 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/25992746/pubmed" id="25992746" target="_blank">25992746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2512129">
<a name="2512129"></a>Schaad UB, Wedgwood-Krucko J, Guenin K, Buehlmann U, Kraemer R. Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. <i>Eur J Clin Microbiol Infect Dis</i>. 1989;8(10):858-865. doi:10.1007/BF01963771<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/2512129/pubmed" id="2512129" target="_blank">2512129</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Settler FR, Schramm M, and Swabb EA, “Safety of Aztreonam and SQ 26,992 in Elderly Patients With Renal Insufficiency,” <i>Rev Infect Dis</i>, 1985, (Suppl 4):5622.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Smink.1">
<a name="Smink.1"></a>Smink D. Soybel DI. Management of acute appendicitis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 12, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034345">
<a name="20034345"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America (SIS/IDSA). <i>Clin Infect Dis.</i> 2010;50(2):133-164. doi:10.1086/649554<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/20034345/pubmed" id="20034345" target="_blank">20034345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Southwick.1">
<a name="Southwick.1"></a>Southwick FS. Treatment and prognosis of bacterial brain abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 5, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spelman.1">
<a name="Spelman.1"></a>Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3766490">
<a name="3766490"></a>Stutman HR, Chartrand SA, Tolentino T, et al, “Aztreonam Therapy for Serious Gram-Negative Infections in Children,” <i>Am J Dis Child</i>, 1986, 140(11):1147-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/3766490/pubmed" id="3766490" target="_blank">3766490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6541452">
<a name="6541452"></a>Stutman HR, Marks MI, Swabb EA. Single-dose pharmacokinetics of aztreonam in pediatric patient<i>s. Antimicrob Agents Chemother.</i> 1984;26(2):196-199. doi:10.1128/aac.26.2.196<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/6541452/pubmed" id="6541452" target="_blank">6541452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3909336">
<a name="3909336"></a>Swabb EA, Jenkins SA, Muir JG. Summary of worldwide clinical trials of aztreonam in patients with urinary tract infections. <i>Rev Infect Dis</i>. 1985;7(suppl 4):S772-S777. doi:10.1093/clinids/7.supplement_4.s772<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/3909336/pubmed" id="3909336" target="_blank">3909336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35439291">
<a name="35439291"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). <i>Clin Infect Dis</i>. 2022b;75(2):187-212. doi:10.1093/cid/ciac268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/35439291/pubmed" id="35439291" target="_blank">35439291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34864936">
<a name="34864936"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. <i>Clin Infect Dis</i>. 2022a;74(12):2089-2114. doi:10.1093/cid/ciab1013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/34864936/pubmed" id="34864936" target="_blank">34864936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27025644">
<a name="27025644"></a>Tennant SJ, Burgess DR, Rybak JM, Martin CA, Burgess DS. Utilizing Monte Carlo simulations to optimize institutional empiric antipseudomonal therapy. <i>Antibiotics (Basel)</i>. 2015;4(4):643-652. doi:10.3390/antibiotics4040643<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/27025644/pubmed" id="27025644" target="_blank">27025644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27132188">
<a name="27132188"></a>Thompson RZ, Martin CA, Burgess DR, Rutter WC, Burgess DS. Optimizing beta-lactam pharmacodynamics against Pseudomonas aeruginosa in adult cystic fibrosis patients. <i>J Cyst Fibros.</i> 2016;15(5):660-663. doi:10.1016/j.jcf.2016.04.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/27132188/pubmed" id="27132188" target="_blank">27132188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16163635">
<a name="16163635"></a>Trotman RL, Williamson JC, Shoemaker DM, et al, "Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy," <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/16163635/pubmed" id="16163635" target="_blank">16163635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2731447">
<a name="2731447"></a>Trujillo H, Harry N, Arango A, et al. Aztreonam in the treatment of aerobic, gram-negative bacillary infections in pediatric patients. <i>Chemotherapy</i>. 1989;35(suppl 1):S25-S30. doi:10.1159/000238717<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/2731447/pubmed" id="2731447" target="_blank">2731447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494903">
<a name="15494903"></a>Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis</i>. 2004;39(9):1267-1284. doi:10.1086/425368<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/15494903/pubmed" id="15494903" target="_blank">15494903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203777">
<a name="28203777"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. <i>Clin Infect Dis</i>. 2017;64(6):e34-e65. doi:10.1093/cid/ciw861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/28203777/pubmed" id="28203777" target="_blank">28203777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet.</i> 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2186351">
<a name="2186351"></a>Umaña MA, Odio CM, Castro E, Salas JL, McCracken GH Jr. Evaluation of aztreonam and ampicillin vs. amikacin and ampicillin for treatment of neonatal bacterial infections. <i>Pediatr Infect Dis J</i>. 1990;9(3):175-180. doi:10.1097/00006454-199003000-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/2186351/pubmed" id="2186351" target="_blank">2186351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vollmer.1">
<a name="Vollmer.1"></a>Vollmer CM, Zakko SF, Afdhal NH. Treatment of acute calculous cholecystitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851742">
<a name="22851742"></a>Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. <i>Perit Dial Int</i>. 2012;32(Suppl 2):S32-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/22851742/pubmed" id="22851742" target="_blank">22851742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weintrob.1">
<a name="Weintrob.1"></a>Weintrob AC, Sexton DJ. Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 4, 2023.</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27530649">
<a name="27530649"></a>Xu H, Zhou W, Zhou D, Li J, Al-Huniti N. Evaluation of aztreonam dosing regimens in patients with normal and impaired renal function: a population pharmacokinetic modeling and Monte Carlo simulation analysis. <i>J Clin Pharmacol.</i> 2017;57(3):336-344. doi:10.1002/jcph.810<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/27530649/pubmed" id="27530649" target="_blank">27530649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30535100">
<a name="30535100"></a>Yahav D, Franceschini E, Koppel F, et al; Bacteremia Duration Study Group. Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial. <i>Clin Infect Dis</i>. 2019;69(7):1091-1098. doi:10.1093/cid/ciy1054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/30535100/pubmed" id="30535100" target="_blank">30535100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22911974">
<a name="22911974"></a>Zobell JT, Young DC, Waters CD, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. <i>Pediatr Pulmonol</i>. 2012;47(12):1147-1158.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/22911974/pubmed" id="22911974" target="_blank">22911974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23359557">
<a name="23359557"></a>Zobell JT, Young DC, Waters CD, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive Summary. <i>Pediatr Pulmonol</i>. 2013;48(6):525-537. doi: 10.1002/ppul.22757.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/23359557/pubmed" id="23359557" target="_blank">23359557</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 104181 Version 133.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
